Clinical trial
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
NCT00369174 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00369174 |
|---|---|
| Title | Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia |
| Official title | Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Oral Leukoplakia |
| Intervention type | Drug, Other |
| Interventions | rosiglitazone maleate, laboratory biomarker analysis |
| Enrollment | 25 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2007 |
| First posted | Aug 29, 2006 |
| Last update posted | Feb 13, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: